Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot study on allogeneic stem cell transplant following conditioning with fludarabine and an alkylating agent in patients with high-risk chornic lymphocytic leukemia.

Next Previous
X
Search
Trial Profile

Pilot study on allogeneic stem cell transplant following conditioning with fludarabine and an alkylating agent in patients with high-risk chornic lymphocytic leukemia.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab; Antineoplastics; Antithymocyte globulin; Busulfan; Busulfan; Ciclosporin; Cyclophosphamide; Filgrastim; Fludarabine; Methotrexate; Mycophenolate mofetil; Rituximab; T cell replacement therapy
  • Indications Chronic lymphocytic leukaemia; Graft-versus-host disease; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 24 Jul 2017 Biomarkers information updated
    • 01 Jul 2010 Results published online in Blood, according to an American Society of Hematology media release.
    • 08 Feb 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top